Porton(SZ:300363) Ping An Securities·2025-10-30 11:06Investment Rating - The report maintains a "Recommended" rating for the company [5][8]. Core Views - The company reported a significant improvement in performance, with Q3 2025 revenue reaching 0.923 billion yuan, a year-over-year increase of 19.44%, and a net profit of 0.053 billion yuan, up 245.24% year-over-year [5][8]. - The report highlights that multiple factors are driving the improvement in profit margins, including a 19% year-over-year revenue growth in the small molecule CDMO business and a 255% increase in revenue from new molecular business [8]. - The company is expected to see continuous improvement in profitability, with revised net profit forecasts for 2025-2027 being 1.17 billion yuan, 2.70 billion yuan, and 5.12 billion yuan, respectively [8]. Financial Summary - For the fiscal year 2024, the company is projected to have a revenue of 3.012 billion yuan, with a year-over-year decline of 17.9%, followed by a recovery in subsequent years [7][10]. - The net profit for 2024 is expected to be -0.288 billion yuan, with a significant turnaround anticipated in 2025 with a projected profit of 0.117 billion yuan [9][10]. - The gross margin is expected to improve from 24.6% in 2024 to 37.2% by 2027, indicating a positive trend in profitability [10]. Market Position - The company operates in the pharmaceutical industry, with a total market capitalization of 15.1 billion yuan and a circulating A-share market value of 13.8 billion yuan [5][8]. - The major shareholder is Chongqing Liangjiang New Area Industrial Development Group Co., Ltd., holding 14.48% of the shares [5].